Cargando…
Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa
Lysosomal acid lipase deficiency (LAL-D) is a rare disorder of cholesterol metabolism with an autosomal recessive mode of inheritance. The absence or deficiency of the LAL enzyme gives rise to pathological accumulation of cholesterol esters in various tissues. A severe LAL-D phenotype manifesting in...
Autores principales: | Su, Kim, Donaldson, Emma, Sharma, Reena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074735/ https://www.ncbi.nlm.nih.gov/pubmed/27799810 http://dx.doi.org/10.2147/TACG.S86760 |
Ejemplares similares
-
Sebelipase alfa for lysosomal acid lipase deficiency: 5‐year treatment experience from a phase 2 open‐label extension study
por: Malinová, Vĕra, et al.
Publicado: (2020) -
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
por: Jones, Simon A., et al.
Publicado: (2017) -
Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization
por: Huffaker, Michelle F., et al.
Publicado: (2019) -
Clinical outcome of a patient with lysosomal acid lipase deficiency and first results after initiation of treatment with Sebelipase alfa: A case report
por: Soll, Dominik, et al.
Publicado: (2019) -
Correction to: Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization.
Publicado: (2020)